April 10 Looms as Eli Lilly’s Next Big Test: Is the Stock a Buy Before the FDA Verdict? Mar 22, 2026 Life Science
Hims & Hers Joins Hands with Former Rival, Hidden Concerns Loom Over the Weight Loss Drug Market Landscape Mar 18, 2026 Life Science
How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era? Mar 17, 2026 Life Science
Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally Mar 16, 2026 Life Science
Novo Nordisk Partners with Hims & Hers: Can Turning a Foe into a Friend Reverse the Downturn? Mar 13, 2026 Life Science
Why Microsoft Is a Safe Bet in the AI Era, Despite Moderate Stock Gains Mar 13, 2026 Life Science, Technology
Seeking a Bottom in Choppy Markets? Two Long-Term Picks with “Anti-Fragile” Qualities Mar 12, 2026 Life Science, Technology
The Obesity Drug War Goes Oral: Why Eli Lilly’s Orforglipron Could Steal the Spotlight from Novo Mar 11, 2026 Life Science
This Stock Soared 1600% in a Year! Billionaire Cohen Had Already Positioned Himself Mar 11, 2026 Life Science
A Tenfold Increase in a Decade? What Makes This Small Biotech Company So Special Mar 10, 2026 Life Science
Novo Nordisk’s Price Cuts and R&D Progress Go Hand in Hand, GLP-1 Drug Prices Reduced by Up to 50% Mar 10, 2026 Life Science
$70 Billion and Counting: The 5 US Dividend Giants That Keep on Giving Mar 9, 2026 Energy, Financial Service, Life Science, Technology
